Skip to main content

Published locations for Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems

User login

  • Reset your password
  • /content/romosozumab-reduces-fracture-risk-out-36-months-no-signs-cardiovascular-problems
  • /familypracticenews/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no
  • /internalmedicinenews/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no
  • /rheumatologynews/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no
  • /clinicalendocrinologynews/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36
  • /endocrinology/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no-signs
  • /rheumatology/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no-signs
  • /internalmedicine/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no
  • /familymedicine/article/148014/osteoporosis/romosozumab-reduces-fracture-risk-out-36-months-no-signs